Drop in Vytorin scrips slows

Has the Vytorin prescription drop leveled off? The most recent data shows that scrips for the Merck/Schering-Plough cholesterol med only dropped 1.1 percent in May, month-over-month, to 2.5 million. By contrast, the decline was 11 percent from March to April and 23 percent since January. That's when the ill-fated Enhance trial data was released, showing the combo Vytorin--a mix of simvastatin and Zetia--was no better than simvastatin alone at slowing artery-hardening.

The numbers took a big initial hit--13 percent in February, month-over-month--but rebounded a bit in March until the American College of Cardiology meeting, where an expert panel recommended using Vytorin only after a host of other cholesterol meds proved ineffective. That led to the drop in April, and to an aggressive cost-cutting program at Schering-Plough, whose revenue depends heavily on Vytorin and Zetia.

- find the Schering-Plough FAQ for investors
- read the Wall Street Journal story

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.